Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol.

Research paper from Europe PMC. Evidence status: source reported.

Published

2018-05-01

Source reference

MED:29529169

DOI

10.1093/annonc/mdy072

Jurisdiction

Not assessed

Licence

Bibliographic metadata only; article rights retained

Sydes MR, Spears MR, Mason MD, Clarke NW, Dearnaley DP, de Bono JS, Attard G, Chowdhury S, Cross W, Gillessen S, Malik ZI, Jones R, Parker CC, Ritchie AWS, Russell JM, Millman R, Matheson D, Amos C, Gilson C, Birtle A, Brock S, Capaldi L, Chakraborti P, Choudhury A, Evans L, Ford D, Gale J, Gibbs S, Gilbert DC, Hughes R, McLaren D, Lester JF, Nikapota A, O'Sullivan J, Parikh O, Peedell C, Protheroe A, Rudman SM, Shaffer R, Sheehan D, Simms M, Srihari N, Strebel R, Sundar S, Tolan S, Tsang D, Varughese M, Wagstaff J, Parmar MKB, James ND, STAMPEDE Investigators. · Ann Oncol · clinical trial, phase iii; clinical trial, phase ii; research support, non-u.s. gov't; research-article; multicenter study; randomized controlled trial; journal article · Found via: ClinicalTrials.gov result publication

Source: https://europepmc.org/article/MED/29529169. Captured 2026-10-24.

Limitations: Listed by a ClinicalTrials.gov registration as a result publication of that study, and fetched by its PubMed ID. The registry's listing is the sponsor's statement; it does not confirm which data the paper used. Preprints may not be peer reviewed.